UK needs a devices industry leader to avoid "pharma drift"
This article was originally published in Clinica
The UK medical devices industry is calling for the clear identification within the Medicines and Healthcare products Regulatory Agency (MHRA) of an individual who should be responsible for continuing to fight at European level for "commonsense and pragmatic solutions" to medical device regulatory problems, according to Malcolm Carlisle, group managing director of Eschmann Holdings.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.